Medical Oncologist
Medicines
How does sacituzumab govitecan work, and who is it for?
Sacituzumab govitecan joins an antibody that finds TROP2 on breast cancer cells to a strong chemotherapy payload. It is used for advanced triple-negative breast cancer and for advanced hormone receptor-positive, HER2-negative breast cancer after earlier treatments. This page explains how it works, where it fits and what your team checks before you start.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
On this page
- How does sacituzumab govitecan work?
- From drip to cancer cell, in four stages
- Where sacituzumab govitecan fits
- The vocabulary, in plain language
- Honest realities about this medicine
- How it differs from other breast cancer medicines
- What your team will check first
- What people assume about how it works
- Common questions about how sacituzumab govitecan works
The short answer
How does sacituzumab govitecan work?
Sacituzumab govitecan, brand name Trodelvy, is an antibody-drug conjugate. That means it joins two things together: an antibody that seeks out a protein called TROP2, and a strong chemotherapy payload called SN-thirty-eight, which is the active form of the older medicine irinotecan. TROP2 sits on the surface of most breast cancer cells, usually in much larger amounts than on healthy tissue. The antibody acts like a delivery address, carrying the chemotherapy to cells that carry TROP2. Once the medicine attaches, the cell takes it in and the payload is released, damaging the cell's DNA so it cannot divide. Some payload is also released just outside the cell, where it can reach nearby cancer cells that have less TROP2, which is sometimes called the bystander effect. Because the payload is still chemotherapy, some reaches healthy fast-dividing cells too, which is why low white cell counts, diarrhoea, nausea and hair loss can happen. It is used for breast cancer that has spread or cannot be removed by surgery. It is approved for triple-negative breast cancer after earlier treatments, and for hormone receptor-positive, HER2-negative breast cancer after hormone treatments and further chemotherapy. You do not need a special TROP2 test to have it. Trials are also testing it at earlier points, so what is offered continues to change.
A targeted delivery system
The antibody guides a chemotherapy payload towards cancer cells carrying TROP2.
Still a form of chemotherapy
The payload is powerful, so side effects are real and need careful monitoring.
For advanced breast cancer
It is used when breast cancer has spread or cannot be operated on, after earlier treatments.
This page gives general information only. Whether this medicine suits you depends on your cancer type, earlier treatment and health, and is decided with your oncologist.Step by step
From drip to cancer cell, in four stages
A simplified picture of what happens after the medicine enters your bloodstream.
Finding the target
The antibody part travels in the blood and attaches to TROP2 on the surface of cancer cells.
Getting inside
The cell pulls the attached medicine inside, carrying the chemotherapy payload with it.
This is what makes it an antibody-drug conjugate.Releasing the payload
The link breaks down and SN-thirty-eight is freed. It blocks an enzyme the cell needs to copy its DNA, so the cell dies.
Reaching neighbours
Some payload escapes into the surrounding area and can affect nearby cancer cells, including those with less TROP2.
Why this matters
- Breast tumours vary cell to cell
- No TROP2 test is needed
- Healthy cells can be affected too
Who it is for
Where sacituzumab govitecan fits
Situation
Usual position
Advanced triple-negative breast cancer
Approved after two or more earlier treatments, at least one for advanced disease
Advanced hormone receptor-positive, HER2-negative
Approved after hormone treatment and further chemotherapy for advanced disease
HER2-positive breast cancer
Not a standard option; HER2-targeted medicines are used instead
Early breast cancer after surgery
Not a routine option; being studied in trials
First treatment for advanced disease
Being studied; ask whether newer results apply to you
Words you will hear
The vocabulary, in plain language
- Antibody-drug conjugate
- A medicine that joins an antibody to a chemotherapy payload so it is carried towards cancer cells.
- TROP2
- A protein found on the surface of many breast cancer cells, used as the target.
- Payload
- The cell-killing chemotherapy part of the medicine, here SN-thirty-eight.
- Triple-negative
- Breast cancer without oestrogen receptors, progesterone receptors or extra HER2.
- Hormone receptor-positive
- Breast cancer whose growth is fuelled by oestrogen or progesterone.
- UGT1A1
- A gene that affects how the body clears the payload; some variants raise the risk of low white cell counts.
Talk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Being straight with you
Honest realities about this medicine
Sacituzumab govitecan is an important option for advanced breast cancer, but it is worth being clear about what it can and cannot do.
It aims to control, not remove, advanced cancer
In trials it helped people live longer and kept the cancer controlled for longer than standard chemotherapy on average. For breast cancer that has spread, the aim is control and quality of life.
Targeted does not mean gentle
Low white cell counts and diarrhoea can be serious. Most people need close monitoring, and many need dose delays or reductions.
Not everyone responds
Some cancers shrink, some stay stable and some keep growing. Scans every few cycles show which applies to you.
What this page cannot tell you
It cannot tell you whether this medicine is the right next step for you, how well it will work for your cancer, or whether it is available and funded in your situation.
In context
How it differs from other breast cancer medicines
People often hear several similar-sounding names. A little background helps you follow the conversation with your team.
Compared with standard chemotherapy
Standard chemotherapy spreads through the whole body with no targeting. Sacituzumab govitecan uses an antibody to concentrate its payload near cancer cells, though some still reaches healthy tissue.
Compared with other antibody-drug conjugates
Trastuzumab emtansine and trastuzumab deruxtecan target HER2 instead of TROP2 and carry different payloads. Datopotamab deruxtecan also targets TROP2. Each has its own side effects and approved uses.
Compared with immunotherapy
Immunotherapy such as pembrolizumab helps the immune system attack cancer and is used in some triple-negative breast cancers. Sacituzumab govitecan kills cells directly through its payload.
Before you start
What your team will check first
A few checks help your team decide whether this medicine is suitable and how to keep you safe on it.
Your earlier treatments and biopsy results
Your team confirms your receptor status and which treatments you have already had, because approval depends on that history.
Blood tests
Blood counts, liver function and kidney function are checked. Some centres test the UGT1A1 gene, as people with certain variants may need closer watching for low white cell counts.
Other medicines and pregnancy
Tell your team about all medicines and supplements, as some affect how the payload is cleared. This medicine can harm an unborn baby, so reliable contraception is needed during treatment and for some months afterwards.
Commonly believed
What people assume about how it works
Targeted medicines only touch cancer cells.
The payload can still affect healthy cells, so side effects are expected.
I need a positive TROP2 test to get it.
No TROP2 test is required for its approved uses in breast cancer.
It works for every type of breast cancer.
Its approved uses are specific advanced HER2-negative breast cancers.
It replaces all other treatment options.
It is one option in a sequence your team plans with you.
Questions we are asked
Common questions about how sacituzumab govitecan works
Is sacituzumab govitecan chemotherapy?
Partly. Its payload is a chemotherapy medicine, so it shares many of the side effects of chemotherapy, such as low white cell counts, hair loss and diarrhoea. The antibody part makes it more targeted than standard chemotherapy, which is why it is classed as an antibody-drug conjugate rather than plain chemotherapy.
Why does it cause diarrhoea?
The payload is related to irinotecan, which is well known for affecting the gut lining. Diarrhoea can come early, during or soon after the infusion, or later, days after a dose. Both types can be managed, and your team will give you clear instructions and medicines to use at home.
Can I have it if I had irinotecan before?
Irinotecan is rarely used for breast cancer, but if you have had it for another cancer, tell your team. They will consider how you coped with it and any lasting side effects when deciding whether sacituzumab govitecan is suitable and how closely to monitor you.
How quickly does it start working?
The medicine starts acting from the first infusion, but it takes time to see the effect. Your first scan is usually after a few cycles. Some people notice symptoms such as pain easing earlier, while others feel no change until the scan result is discussed.
Does my TROP2 level affect how well it works?
Studies suggested people whose tumours had more TROP2 may have benefited somewhat more, but people with lower levels benefited too. For that reason, testing TROP2 is not needed to decide whether to use it in its approved breast cancer settings.
Can it be combined with other treatments?
In its approved uses it is usually given on its own. Combinations, for example with immunotherapy, are being tested in trials and some results are encouraging. Ask your oncologist whether any newer approach or trial applies to your situation.
What if I have HER2-low breast cancer?
HER2-low cancers are counted as HER2-negative for this medicine, so it may still be an option. Trastuzumab deruxtecan is another medicine used in HER2-low disease. Your team will explain which order of treatments makes sense for you.
What happens if it stops working?
If scans show the cancer is growing, your team will stop it and discuss other options. These may include different chemotherapy, other targeted medicines, a clinical trial or a greater focus on symptom control. Many people go on to have further treatment.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- National Cancer Institute — Sacituzumab govitecan
- European Medicines Agency — Trodelvy: product information
- Cancer Research UK — Sacituzumab govitecan (Trodelvy)
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.